Inhibikase Therapeutics (IKT) EPS (Weighted Average and Diluted) (2021 - 2026)
Inhibikase Therapeutics (IKT) reported EPS (Weighted Average and Diluted) of -$0.1 for Q1 2026, up 33.33% year-over-year from -$0.08 in Q1 2025, and down 11.11% quarter-over-quarter from -$0.09 in Q4 2025.
Inhibikase Therapeutics (IKT) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.1 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.1, up 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.43 (up 27.12% YoY), and the FY2025 annual result was -$0.49, up 57.76% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.1 in Q1 2026 per IKT's latest filing, from -$0.09 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.87 in Q4 2024 and troughed at -$1.1 in Q2 2022.
- A 5-year average of -$0.49 and a median of -$0.66 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) plunged 488.89% in 2022, then soared 227.94% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.02 in 2022, then soared by 33.33% to -$0.68 in 2023, then surged by 227.94% to $0.87 in 2024, then tumbled by 110.34% to -$0.09 in 2025, then slipped by 11.11% to -$0.1 in 2026.
- Business Quant data shows IKT's EPS (Weighted Average and Diluted) at -$0.1 in Q1 2026, -$0.09 in Q4 2025, and -$0.13 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.09 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.11 |
| Mar 31, 2025 | -0.15 |
| Dec 31, 2024 | 0.87 |
| Sep 30, 2024 | -0.65 |
| Jun 30, 2024 | -0.66 |
| Mar 31, 2024 | -0.73 |
| Dec 31, 2023 | -0.68 |
| Sep 30, 2023 | -0.75 |
| Jun 30, 2023 | -0.94 |
| Mar 31, 2023 | -0.80 |
| Dec 31, 2022 | -1.02 |
| Sep 30, 2022 | -1.06 |
| Jun 30, 2022 | -1.10 |
| Mar 31, 2022 | -0.18 |
| Dec 31, 2021 | -0.20 |
| Sep 30, 2021 | -0.18 |
| Jun 30, 2021 | -0.22 |